ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

RFPs Go Out To Cooperative Groups for Community Programs

April 9, 1976

American Cancer Society Elects Officers, Distributes Awards

November 24, 1995

NCI Cooperative Group, Cancer Center Trials Listed

November 28, 2008

In Brief: Oldham to Leave NCI, Herberman Acting Head Of BRMP; Lansky Appointed Director Of ICC

November 11, 1983

Control Finally Gets A Leader–Diane Fink–With An In-House Promotion; NCI Says It Will Spend All The Program’s $34 Million

March 1, 1974

Cooney to Oversee University of Michigan Clinical Operations

February 7, 2013